Categories Earnings, Health Care

BioLineRx (BLRX): Q3 2019 Earnings Snapshot

—  BiolineRX (NASDAQ: BLRX) reported third quarter 2019 operating loss of $6.6 million vs. $6.2 million loss in the year-over period.

— Net loss per share was cents per share, narrower than a loss of 6 cents per share last year, due to higher share count.

— R&D expenses rose 11% to $5.6 million, primarily due to costs associated with the BL-8040 GENESIS and COMBAT/KEYNOTE-202 clinical trials. Results expected by the end of the year.

— BLRX shares are down 75% so far this year.

Browse through our earnings calendar and get all scheduled earnings announcements, analyst/investor conference and much more!

Most Popular

Here’s a look at Dollar Tree’s (DLTR) expectations for the remainder of the year

Shares of Dollar Tree Inc. (NASDAQ: DLTR) were down over 1% on Wednesday, a day after the company reported earnings results for the third quarter of 2022. Revenue and earnings

Target Corporation (TGT): A look at how the retail giant is shaping up against an inflationary backdrop

Shares of Target Corporation (NYSE: TGT) were up over 1% on Wednesday. The stock has dropped 30% year-to-date and 35% over the past 12 months. Last week the company reported

Is Zoom Video Communications (ZM) a good investment after Q3 earnings?

Zoom Video Communications (NASDAQ: ZM) expanded its customer base at an accelerated pace during the COVID crisis and soon became the preferred video conferencing platform for businesses and millions of

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top